# Fast-Track BioPharma Manufacturing With Virtual Twin as a Service
Speed up tech transfer and enhance productivity with a virtual twin of your biopharma manufacturing lines and processes managed by our experts.
**Biopharmaceutical manufacturing** is undergoing major changes. Rising demands for novel therapeutic approaches such as precision medicine, emerging technologies and efforts to build resilient supply chains are pushing **biopharma** manufacturers around the globe to increase their investments1 and transform their operations.
Now is the time to act for companies who have understood that **biotechnology** requires a manufacturing transformation to effectively transform patients’ lives.
## (CS) Accelerating Tech Transfer Drives Progress
Getting a new drug to market can take up to a decade. The **tech transfer** process from clinical and pre-clinical development to manufacturing alone can last up to 24 months and require costly operational changes – time and money that biopharma manufacturers and contract development and manufacturing organizations (**CDMOs**) can’t afford to waste if they want to remain competitive.
Fortunately, there’s a way to speed things up.
## (CS) Rethink BioPharma Manufacturing With Virtual Twin Technology
Virtual twin technology is set to revolutionize and accelerate **biopharma manufacturing** by empowering manufacturers to virtually model, simulate and validate their bioprocesses, products and production lines.
Using data-driven insights, manufacturing processes, equipment and factories are modeled, simulated and analyzed. In biopharma, this approach is already being used to virtually commission manufacturing lines, run airflow simulations in cleanrooms, and test layout and flow options as well as robot and operator optimizations. The result? Faster, more efficient and sustainable processes.
## (CS) Virtual Twin As a Service Advantage
View infographic
View infographic
## (CS) Get to Market Faster With BioPharma Manufacturing Virtual Twin as a Service
By combining Dassault Systèmes’ virtual twin technology and expertise, BioPharma Manufacturing Virtual Twin as a Service (VTaaS) provides manufacturers with tailored solutions to accelerate tech transfer while improving productivity, cost efficiency and quality.
BioPharma Manufacturing Virtual Twin as a Service is a [GxP-ready](/3dexperience-platform/gxp-readiness "GxP Readiness on 3DEXPERIENCE") cloud-based subscription service that adapts to your budgets, priorities and goals. No need for specific software, skillsets or dedicated personnel – leveraging the **3D**EXPERIENCE® platform’s advanced capabilities and over 40 years of industry know-how, our experts create, implement and maintain a virtual twin of your operations for you so you can focus on your essential business targets.
Virtual Twin as a Service models lines and processes, simulates their behavior and generates insights into your entire production system, including equipment, resources and facilities, which enables you to optimize, virtually commission and qualify pharmaceutical lines in accordance with **good manufacturing practices** (GMP) before physically implementing them.
## (CS) Discover BioPharma Manufacturing Virtual Twin as a Service
Learn how Virtual Twin as a Service empowers biopharma manufacturers to optimize tech transfer and scale up at speed.
[(CS) Virtual Twin as a Service – BioPharma Manufacturing](/media/21492)
[ Watch now ](/media/21482)
## (CS) Achieve Long-Lasting Value in Record Time
BioPharma Manufacturing Virtual Twin as a Service, enhanced by **artificial intelligence** (AI), machine learning and generative design solutions, enables you to optimize existing **biopharmaceutical manufacturing equipment** and quickly **scale up** new production lines while preparing your business for future challenges.
## (CS) Optimize before you start:
- Integrate and optimize fill and finish lines, pharma processes and automation
- Minimize downtime between changeovers
- Reduce errors and increase workplace safety
- Prevent cross-contamination risks and ensure cleanroom compliance
## (CS) Fast-track tech transfer:
- Reduce line and process engineering time
- Improve line reconfiguration and equipment setup
- Virtually verify and validate tests to achieve regulatory compliance
- Increase speed across fill and finish and packaging lines
## (CS) Get future-ready:
- Achieve sustainability targets by reducing waste, carbon emissions and water and energy consumption
- Standardize processes and equipment configurations to identify opportunities for reuse and plan line configurations
- Capitalize know-how to prepare for AI-driven manufacturing optimization
## (CS) Transform Fill and Finish in Biopharma
Discover how virtual twins can help biopharma manufacturers improve agility, reduce risk and accelerate time to market at this critical stage.
[(CS) Transform Fill and Finish in Biopharma Highlight](/media/22772)
[ Read free white paper ](/media/22773)
## (CS) Frequently Asked Questions
## What is biopharmaceutical manufacturing?
**Biopharmaceutical manufacturing** is the process of producing **biological drugs** – also called **biologics** – which are complex medicines made from living cells or organisms. Most of them are monoclonal antibodies, vaccines, gene therapies, recombinant proteins, and cell therapies **used to treat** cancer, autoimmune diseases, rare genetic disorders and more.
## What is the difference between pharma and biopharma?
Biopharmaceutical products are manufactured in or sourced from biological or semi-synthetic sources, while the traditional pharmaceutical industry creates drugs which are typically synthesized chemically. Biologics are sensitive to small changes in environment or process and require major investment and control to move from lab-scale to industrial production.
## What are the key challenges of the biopharma manufacturing process?
The main challenges faced by biopharmaceutical manufacturers are:
- **Capacity:** Manufacturers need to increase manufacturing capacity to produce new and [personalized medicines](/industries/life-sciences-healthcare/precision-medicine "Precision Medicine Meets Biomanufacturing Excellence") such as biologics for autoimmune disorders, mRNA therapies and cell and gene therapies (CGT). In addition, these are often packaged in innovative delivery devices, which is a challenge in itself for manufacturers.
- **Organization:** Companies must synchronize different disciplines and production plants to minimize bottlenecks and delays.
- **Time to market:** Being first to market is a key differentiator in a highly competitive industry, but lengthy development and tech transfer times can make it challenging to achieve.
- **Sustainability:** Manufacturers must meet environmental objectives to reduce waste, carbon emissions and energy usage.
- **Cost reduction:** Investments associated with new therapy development, facility setup, and labor hiring and training can quickly add to existing operational costs.
- **Regulatory compliance:** Manufacturers must stay up to date with current and upcoming regulations to bring a new drug to market.
## What can a biopharmaceutical company do to accelerate its tech transfer process?
Biopharmaceutical companies that want to accelerate their tech transfer process can harness **digital technologies** such as [virtual twins](https://blog.3ds.com/industries/life-sciences-healthcare/from-lab-to-life-how-virtual-twins-are-revolutionizing-biopharma-manufacturing/%20) to virtually optimize production before physical implementation with **process and production line simulation, supply chain planning, aseptic air flow simulation** and [virtual commissioning and qualification](https://discover.3ds.com/optimize-pharmaceutical-manufacturing-virtual-commissioning) solutions.
## What is BioPharma Manufacturing Virtual Twin as a Service?
BioPharma Manufacturing Virtual Twin as a Service (VTaaS) is a cloud-based managed service available through a single subscription that combines virtual twin technology and Dassault Systèmes’ expert knowledge to provide biopharma companies and CDMOs with data-driven insights of their processes and production lines based on virtual twin technology.
This service provides manufacturers with virtual replicas of processes, products and production lines that enable them to quickly and easily model, test and simulate manufacturing alternatives virtually before implementing them in the real world.
## What are the benefits of BioPharma Manufacturing Virtual Twin as a Service for biopharma companies and CDMOs?
BioPharma Manufacturing Virtual Twin as a Service (VTaaS) is an online managed service that accelerates time to value by adapting to biopharma companies’ budgets, requirements and business objectives thanks to its flexible subscription model that scales according to business needs.
It provides biopharma manufacturers and CDMOs with the expertise they need to quickly and cost-effectively model and simulate a virtual twin of their processes and production lines. The virtual twin is built, operated and maintained by Dassault Systèmes experts on the **3D**EXPERIENCE platform on the cloud – no need for dedicated software, skillsets or personnel – so biopharma manufacturers can quickly start [generating value](https://blog.3ds.com/topics/thought-leadership/changing-the-time-to-value-equation-with-virtual-twin-as-a-service/) while reducing costs and risks.
BioPharma Manufacturing VTaaS empowers biopharma manufacturers to optimize their operations, increase drug quality, improve productivity and speed up tech transfer from formulation to production by:
- Optimizing new and existing production lines before physical implementation
- Speeding up tech transfer between R&D and manufacturing by up to 30%
- Increasing productivity in OEE by up to 20%
*\[1\] Source:*[ *Pharmamanufacturing - Big Pharma doubles down on manufacturing investments*](https://www.pharmamanufacturing.com/editors-review/article/55248018/big-pharma-doubles-down-on-manufacturing-investments)
## ## Learn More About Our Solutions
## (CS) Ready to learn more?
See how you can get the most out of your digital transformation with Virtual Twin as a Service. Whether you want to speed up time to market for your drugs, create a new production line or optimize an existing one, our experts are here for you. Fill out the form to get in touch today.
Contact us
WFC26127
Thank you for your interest. The sales team will respond as soon as possible.
## (CPS) Ready to learn more?
Contact us
Contact us to learn more
Read free white paper
BioPharma